Evidence map›Paper›PMID 37123531›Full record

ArticleEvolutionary bioinformatics online2023

In Silico Analyses of All STAT3 Missense Variants Leading to Explore Divergent AD-HIES Clinical Phenotypes.

Mariam Mansouri, Ghyzlane El Haddoumi, Houda Bendani, Nasma Boumajdi, Mohammed Hakmi, Hanane Abbou, El Mehdi Bouricha, Boutaina Elgharbaoui, Souad Kartti, Rachid El Jaoudi and 4 more

Open access · goldAbstract read
In one paragraph

Article in Evolutionary bioinformatics online, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. International journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Mariam MansouriBiotechnology lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Morocco.ORCID https://orcid.org/0000-0003-4408-7593
Ghyzlane El HaddoumiBiotechnology lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Morocco.
Houda BendaniBiotechnology lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Morocco.
Nasma BoumajdiBiotechnology lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Morocco.
Mohammed HakmiBiotechnology lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Morocco.
Hanane AbbouCentre Mohammed VI of Research and Innovation (CM6), Rabat, Morocco.
El Mehdi BourichaBiotechnology lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Morocco.
Boutaina ElgharbaouiBiotechnology lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Morocco.
Souad KarttiBiotechnology lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Morocco.
Rachid El JaoudiBiotechnology lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Morocco.
Lahcen BelyamaniCentre Mohammed VI of Research and Innovation (CM6), Rabat, Morocco.
Ilham KandoussiBiotechnology lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Morocco.
Azeddine IbrahimiBiotechnology lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Morocco.
Naima El HafidiBiotechnology lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Morocco.ORCID https://orcid.org/0000-0002-8427-8805
Mohammed V University · MAUniversité Mohammed VI des Sciences et de la Santé · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal dominant hyper-IgE syndrome (AD-HIES) is linked to dominant negative mutations of the STAT3 protein whose molecular basis for dysfunction is unclear and presenting with a variety of clinical manifestations with only supportive treatment. To establish the relationship between the impact of STAT3 mutations in different domains and the severity of the clinical manifestations, 105 STAT3 mutations were analyzed for their impact on protein stability, flexibility, function, and binding affinity using in Silico approaches. Our results showed that 73% of the studied mutations have an impact on the physicochemical properties of the protein, altering the stability, flexibility and function to varying degrees. In particular, mutations affecting the DNA binding domain (DBD) and the Src Homology 2 (SH2) have a significant impact on the protein structure and disrupt its interaction either with DNA or other STAT3 to form a heterodomain complex, leading to severe clinical phenotypes. Collectively, this study suggests that there is a close relationship between the domain involving the mutation, the degree of variation in the properties of the protein and the degree of loss of function ranging from partial loss to complete loss, explaining the variability of clinical manifestations between mild and severe.

Indexed as

Autosomal dominant hyper-IgE syndromecomputational screeningmutational effectsprotein flexibility and stabilitySTAT3 mutations

Identifiers

PMID37123531
PMCPMC10134169
OpenAlexW4366963630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.